Author + information
- Received February 19, 2016
- Revision received April 1, 2016
- Accepted April 18, 2016
- Published online April 3, 2017.
- Sanghoon Shin, MDa,b,
- Hyung-Bok Park, MDb,c,
- Hyuk-Jae Chang, MDb,∗ (, )
- Reza Arsanjani, MDd,
- James K. Min, MDe,
- Yong-Jin Kim, MD, PhDf,
- Byoung Kwon Lee, MDg,
- Jung-Hyun Choi, MDh,
- Geu-Ru Hong, MDb and
- Namsik Chung, MDb
- aDivision of Cardiology, Department of Internal Medicine, NHIS Ilsan Hospital, Goyang-si, Gyeonggi-do, South Korea
- bDivision of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea
- cDivision of Cardiology, Department of Internal Medicine, Myungji Hospital, Goyang-si, Gyeonggi-do, South Korea
- dMayo Clinic, Division of Cardiology, Department of Internal Medicine, Scottsdale, Arizona
- eWeill Cornell Medical College and the New York-Presbyterian Hospital, New York, New York
- fDivision of Cardiology, Seoul National University Hospital, Seoul, South Korea
- gDivision of Cardiology, Gangnam Severance Hospital, Seoul, South Korea
- hDivision of Cardiology, Busan Medical Center, Busan, South Korea
- ↵∗Address for correspondence:
Dr. Hyuk-Jae Chang, Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, South Korea.
Objectives The aim of this study was to explore the relationship between temporal changes in coronary plaque volume and the intensity of lipid-lowering treatments, utilizing coronary computed tomography angiography (CTA).
Background Coronary CTA has acceptable accuracy in terms of quantitative measurement of plaque volume. Although, coronary CTA is perhaps capable of identifying the differences in plaque volume progression according to the intensity of lipid lowering treatment, to date, few studies have examined this notion.
Methods In this multicenter, observational study, the authors reviewed 467 patients who underwent serial coronary CTA with a scan period of more than 2 years (median 3.2 years [2.4 to 4.8]) apart, and whose laboratory data were available within 1 month of both the baseline and follow-up coronary CTA. Among them, 147 patients (comprising 336 vessels) with visible plaque were enrolled in this study. The authors performed quantitative assessment of coronary plaque in both. Patients who achieved a low-density lipoprotein cholesterol (LDL-C) with a cut off value below 70 mg/dl at follow-up were compared with those who did not.
Results Patients with LDL-C below 70 mg/dl displayed a significant attenuation in plaque progression as compared with those with follow-up LDL-C levels ≥70 mg/dl (12.7 ± 38.2 mm3 vs. 44.2 ± 73.6 mm3, respectively; p = 0.014). In multivariate analysis, factors influencing plaque progression per year was follow-up LDL-C levels ≥70 mg/dl (beta 0.193; p = 0.021).
Conclusions Strict LDL-C control appeared to significantly attenuate plaque volume progression based on noninvasive quantitative assessment by coronary CTA.
- coronary computed tomography angiography
- coronary plaque quantification
- low-density lipoprotein-cholesterol
This work was supported by the ICT R&D program of MSIP/IITP [10044910, Development of Multi-modality Imaging and 3D Simulation-Based Integrative Diagnosis-Treatment Support Software System for Cardiovascular Diseases]. Dr. Min has received funding from the National Institutes of Health/National Heart, Lung, and Blood Institute (NIH/NIHLBI) grants R01HL111141, R01HL115150, R01HL118019, and U01HL105907, and Qatar National Research Foundation grant NPRP09-370-3-089; is a consultant for HeartFlow; is on the scientific advisory board of Arineta; has ownership of MDDX and Autoplaq; and has a research agreement with GE Healthcare. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Prediman K. Shah, MD, served as the Guest Editor for this paper.
- Received February 19, 2016.
- Revision received April 1, 2016.
- Accepted April 18, 2016.
- 2017 American College of Cardiology Foundation